# Understanding Galectin-3’s Role in Diastolic Dysfunction: A Contemporary Perspective

## TL;DR

This paper reviews how galectin-3 contributes to diastolic dysfunction and its potential as a biomarker and treatment target for heart failure with preserved ejection fraction.

## Contribution

The paper provides a comprehensive review of galectin-3's molecular mechanisms and clinical relevance in diastolic dysfunction.

## Key findings

- Galectin-3 is involved in cardiac remodeling, inflammation, and fibrosis in diastolic dysfunction.
- Evidence from animal and clinical studies supports galectin-3 as a potential biomarker and therapeutic target.
- Understanding galectin-3's role may improve diagnosis and treatment of HFpEF.

## Abstract

Diastolic dysfunction, a prevalent condition characterized by impaired relaxation and filling of the left ventricle, significantly contributes to heart failure with preserved ejection fraction (HFpEF). Galectin-3, a β-galactoside-binding lectin, has garnered attention as a potential biomarker and mediator of fibrosis and inflammation in cardiovascular diseases. This comprehensive review investigates the impact of galectin-3 on diastolic dysfunction. We explore its molecular mechanisms, including its involvement in cellular signaling pathways and interaction with components of the extracellular matrix. Evidence from both animal models and clinical studies elucidates galectin-3’s role in cardiac remodeling, inflammation, and fibrosis, shedding light on the underlying pathophysiology of diastolic dysfunction. Additionally, we examine the diagnostic and therapeutic implications of galectin-3 in diastolic dysfunction, emphasizing its potential as both a biomarker and a therapeutic target. This review underscores the significance of comprehending galectin-3’s role in diastolic dysfunction and its promise in enhancing diagnosis and treatment approaches for HFpEF patients.